Visual Pipeline

OCT has established a pipeline of three types of cannabinoid compounds, from which it is developing medicines in four active programmes. In October 2023, OCT released results from the Phase I single ascending dose clinical trial of its lead drug candidate, OCT461201, marking a significant milestone as the Company transitioned from a pre-clinical to a clinical-stage biopharmaceutical company. Following pre-clinical work on programme 2, OCT130401, targeting trigeminal neuralgia (TN), the programme is now ready to enter Phase I clinical trials, subject to a fundraise.